Peripheral blood stem cell mobilization: The CXCR2 ligand GROβ rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties

2006 ◽  
Vol 34 (8) ◽  
pp. 1010-1020 ◽  
Author(s):  
Louis M. Pelus ◽  
Seiji Fukuda
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Hematopoietic Stem Cells ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
Hematopoietic Stem ◽  
Cell Mobilization ◽  
Cxcr2 Ligand

scholarly journals Identification of Hematopoietic Stem Cells by the SE-9000TM Automated Hematology Analyzer in Peripheral Blood Stem Cell Harvest Samples

1997 ◽  
Vol 98 (1) ◽  
pp. 54-55 ◽  
Author(s):  
Katsuhiro Takekawa ◽  
Takahisa Yamane ◽  
Kenichi Suzuki ◽  
Masayuki Hino ◽  
Noriyuki Tatsumi
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Hematopoietic Stem Cells ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Hematopoietic Stem ◽  
Hematology Analyzer ◽  
Automated Hematology Analyzer ◽  
Cell Harvest

scholarly journals Gemcitabine, Dexamethasone, Cisplatin +/- Rituximab (GDP +/- R) Is Highly Effective As a Mobilization Regimen in Relapsed or Refractory Lymphoma (COLLYM STUDY)

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 3348-3348
Author(s):  
Jean-Philippe Adam ◽  
Vincent T. Taillefer ◽  
Marianne Emond ◽  
Marie-Hélène Leblanc ◽  
Olivier Besner-Morin ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
Secondary Outcome ◽  
Highly Effective ◽  
Refractory Lymphoma ◽  
Cell Mobilization

Abstract Introduction In relapsed or refractory aggressive lymphoma, LY.12 study demonstrated the noninferiority of GDP, in comparison with DHAP, regarding response rate and overall survival with less toxicity. Because GDP ± Rituximab (R) can be easily given in an outpatient setting, this protocol has become the standard of treatment in many centers. However, no data has been published on the method to mobilize stem cells after GDP. The primary objective of the study was to describe the optimal method for a peripheral blood stem cell mobilization following GDP ± R and compare GDP ± R with intermediate-dose cyclophosphamide (ID-CY) as a secondary objective. Method We performed a retrospective observational multicenter study in a cohort of patients treated in one of the three centers located in Montreal and Quebec (CHUM, HMR, HEJ). The study was approved by each local IRB. The inclusion criteria were patients ≥ 18 years with a relapsed of refractory lymphoma who received GDP ± R as a salvage regimen before an autologous stem cells transplantation (ASCT) and who were mobilized on either GDP ± R or ID-CY without the use of plerixafor from January 1st 2014 to April 30th 2017. The GDP regimen consisted of gemcitabine 1000 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 on day 1 and dexamethasone 40 mg once daily on day 1 to 4. Data were collected through the patient electronic health records in each hospital. The primary outcome was to define the percentage of patients achieving ≥ 2 x 106 CD34+/kg, the median CD34 yield, the number of days of apheresis and the initial day of apheresis following GDP ± R plus granulocyte-colony stimulating factor (G-CSF). For the secondary outcome, the same parameters were compared with ID-CY. Continuous and nominal variables were compared using Student's t-test and chi-square test respectively. Results A total of 27 patients with a median age of 54 years received GDP ± R as a salvage therapy for DLBCL (41%), HL (44%) or follicular lymphoma (15%). G-CSF was started at a daily dose of 5 mcg/kg (52%) or 10 mcg/kg (48%) generally at day 9 or 10 and after 2 (67%) or 3 cycles (26%) of GDP ± R. At the first attempt, all patients (100%) achieved the target of ≥ 2 x 106 CD34+/kg with a median of 7.4 x 106 CD34+/kg (2.5-54.1). The median days of apheresis was 2 (1-5) started after a median of 6 days (± 2) following the beginning of G-CSF. In one of the centers (CHUM) a second day of apheresis was automatically planned because the dosage of CD34 in the collected bags was obtained only the next day. Only 1 patient (4%) consulted to the emergency for a slight bleeding at the jugular catheter in a context of thrombocytopenia in the 21 days following the mobilization. A total of 26 patients have proceeded to an ASCT and they had a neutrophils recovery after a median of 11 days (± 4). In the CHUM, 8 and 12 patients were collected following ID-CY and GDP ± R respectively. They were no difference between ID-CY and GDP ± R regarding the target ≥ 2 x 106 CD34+/kg (100 vs 100%, p=NS) but the mean number of CD34+ collected were significantly higher with GDP ± R (23.2 vs 9.6, p=0.02) in less time (2 vs 3 days, p=0.63). There is a trend toward less consultation to emergency and hospitalization within 21 days of mobilization in favor of GDP ± R (8.3% vs 25%, p=0.33). In the ID-CY group, 2 patients were hospitalized for a short follow-up after the removal of the jugular catheter in a context of thrombocytopenia and febrile neutropenia respectively. Conclusion This study demonstrated the feasibility of performing a peripheral blood stem cell mobilization at day 15 following GDP ± R with G-CSF given at day 9 of the second or third cycle. It highly effective and represents a better option due to its simplicity of administration, low rate of hospitalization and low cost. Disclosures Adam: Apobiologix: Honoraria; Novartis: Honoraria; Janssen: Consultancy, Honoraria; Amgen: Honoraria; Abbvie: Consultancy, Honoraria; TEVA: Consultancy. Emond:Roche: Honoraria; Novartis: Consultancy, Honoraria; Genzyme: Consultancy; Lundbeck: Consultancy, Honoraria; Gilead: Consultancy; Jassen: Consultancy, Honoraria; Nycomed: Consultancy; Sanofi-Aventis: Consultancy. Leblanc:Sanofi Aventis: Consultancy. Doucet:Roche: Consultancy; Seattle Genetic: Consultancy; Abbvie: Consultancy; Merck: Consultancy; Jannsen: Consultancy; Lundbeck: Consultancy.

High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma

2001 ◽  
Vol 40 (06) ◽  
pp. 215-220 ◽  
Author(s):  
S. Bielack ◽  
S. Flege ◽  
J. Eckardt ◽  
J. Sciuk ◽  
H. Jürgens ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
High Activity ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
High Dose ◽  
External Radiotherapy ◽  
Primary Tumor Site ◽  
Hematopoietic Stem

Summary Purpose: Despite highly efficacious chemotherapy, patients with osteosarcomas still have a poor prognosis if adequate surgical control cannot be obtained. These patients may benefit from therapy with radiolabeled phosphonates. Patients and Methods: Six patients (three male, three female; seven to 41 years) with unresectable primary osteosarcoma (n = 3) or unresectable recurrent sites of osteosarcomas (n = 3) were treated with high-activity of Sm-153-EDTMP (150 MBq/kg BW). In all patients autologous peripheral blood stem cells had been collected before Sm-153-EDTMP therapy. Results: No immediate adverse reactions were observed in the patients. In one patient bone pain increased during the first 48 hrs after therapy. Three patients received pain relief. Autologous peripheral blood stem cell reinfusion was performed on day +12 to +27 in all patients to overcome potentially irreversible damage to the hematopoietic stem cells. In three patient external radiotherapy of the primary tumor site was performed after Sm-153-EDTMP therapy and in two of them polychemotherapy was continued. Thirty-six months later one of these patients is still free of progression. Two further patients are still alive. However, they have developed new metastases. The three patients who had no accompanying external radiotherapy, all died of disease progression five to 20 months after therapy. Conclusion: These preliminary results show that high-dose Sm-153-EDTMP therapy is feasible and warrants further evaluation of efficacy. The combination with external radiation and polychemotherapy seems to be most promising. Although osteosarcoma is believed to be relatively radioresistant, the total focal dose achieved may delay local progression or even achieve permanent local tumor control in patients with surgically inaccessible primary or relapsing tumors.

Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+cell count to guide pre-emptive or immediate rescue mobilization.

Cytotherapy ◽  
2012 ◽  
Vol 14 (7) ◽  
pp. 823-829 ◽  
Author(s):  
Juan-Manuel Sancho ◽  
Mireia Morgades ◽  
Joan-Ramon Grifols ◽  
Jordi Juncà ◽  
Ramon Guardia ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Count ◽  
Predictive Factors ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
Cell Mobilization

First experience of the use of a generic of plerixafor in peripheral blood stem cell mobilization in multiple myeloma and lymphoma patients

2021 ◽  
pp. 103070
Author(s):  
M.A. Bekadja ◽  
B. Mansour ◽  
H. Ouldjeriouat ◽  
B. Entasoltan ◽  
S. Bouchama ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
Cell Mobilization

High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma

2006 ◽  
Vol 47 (7) ◽  
pp. 1290-1294 ◽  
Author(s):  
Chitra Hosing ◽  
Rima M. Saliba ◽  
Martin Körbling ◽  
Sandra Acholonu ◽  
John Mcmannis ◽  
...  
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
Hodgkin's Lymphoma ◽  
High Dose ◽  
Intermediate Grade ◽  
Non Hodgkin's Lymphoma ◽  
Cell Mobilization

scholarly journals Peripheral Blood Stem Cell Mobilization: a Look Ahead

2018 ◽  
Vol 4 (4) ◽  
pp. 273-281 ◽  
Author(s):  
Louis M. Pelus ◽  
Hal E. Broxmeyer
Keyword(s):  
Stem Cell ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
Look Ahead ◽  
Cell Mobilization

scholarly journals The Effect of Febrile Neutropenia During Peripheral Blood Stem Cell Mobilization on Stem Cell Harvest and Stem Cell Mobilization

LLM Dergi ◽  
2018 ◽  
Vol 2 (3) ◽  
pp. 71-76
Author(s):  
Cemaleddin ÖZTÜRK ◽  
Pervin TOPÇUOĞLU ◽  
Klara DALVA ◽  
Osman İLHAN ◽  
Muhit ÖZCAN
Keyword(s):  
Stem Cell ◽  
Febrile Neutropenia ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Stem Cell Mobilization ◽  
Cell Mobilization ◽  
Cell Harvest
Sign in / Sign up

Export Citation Format

Share Document